By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
NASA Artemis II tracker: Crew less than 60,000 miles from moon ahead of Monday flyby - 2A top Marine shares his secrets to keeping fit at 50
- 37 Heavenly Espressos, One Do You Like?
- 46 Well known Ladies' Fragrances On the planet
- 5Surge of off‑lease electric vehicles expected to drive down used EV prices
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- The Best 15 Applications for Efficiency and Association
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- Find the Standards of Viable Refereeing: Settling Debates with Strategy
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- Trump administration plan to reduce access to some student loans angers nurses, health care groups
- Far-right AfD invited back to Munich Security Conference in 2026
- Why is the Artemis 2 rocket launch different from all other rocket launches?
- We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
